Differential regulation of Ca v 3.2 and Ca v 2.2 calcium channels by CB 1 receptors and cannabidiol
British Journal of Pharmacology · 2023
DOI: 10.1111/bph.16035 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2023. Verfasst von Erika K Harding und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comparative Biology and Experimental Medicine, University of Calgary, Calgary, AB, Canada. Hauptthemen laut MEDLINE: Cannabidiol, Chronic Pain, Cannabinoids. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alberta Innovates, Canadian Institutes of Health Research, Mitacs.
Abstract (Originalsprache)
Background and Purpose Cannabinoids are a promising therapeutic avenue for chronic pain. However, clinical trials often fail to report analgesic efficacy of cannabinoids. Inhibition of voltage gate calcium (Ca v ) channels is one mechanism through which cannabinoids may produce analgesia. We hypothesized that cannabinoids and cannabinoid receptor agonists target different types of Ca v channels through distinct mechanisms. Experimental Approach Electrophysiological recordings from tsA‐201 cells expressing either Ca v 3.2 or Ca v 2.2 were used to assess inhibition by HU‐210 or cannabidiol (CBD) in the absence and presence of the CB 1 receptor. Homology modelling assessed potential interaction sites for CBD in both Ca v 2.2 and Ca v 3.2. Analgesic effects of CBD were assessed in mouse models of inflammatory and neuropathic pain. Key Results HU‐210 (1 μM) inhibited Ca v 2.2 function in the presence of CB 1 receptor but had no effect on Ca v 3.2 regardless of co‐expression of CB 1 receptor. By contrast, CBD (3 μM) produced no inhibition of Ca v 2.2 and instead inhibited Ca v 3.2 independently of CB 1 receptors. Homology modelling supported these findings, indicating that CBD binds to and occludes the pore of Ca v 3.2, but not Ca v 2.2. Intrathecal CBD alleviated thermal and mechanical hypersensitivity in both male and female mice, and this effect was absent in Ca v 3.2 null mice. Conclusion and Implications Our findings reveal differential modulation of Ca v 2.2 and Ca v 3.2 channels by CB 1 receptors and CBD. This advances our understanding of how different cannabinoids produce analgesia through action at different voltage‐gated calcium channels and could influence the development of novel cannabinoid‐based therapeutics for treatment of chronic pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comparative Biology and Experimental Medicine, University of Calgary, Calgary, AB, Canada.
- Department of Clinical Neurosciences, and Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada.
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
- Zymedyne Therapeutics, Calgary, AB, Canada.
ORCID-Profile: Gerald W Zamponi
Förderung
- Alberta Innovates
- Canadian Institutes of Health Research
- Mitacs
Zitieren
APA
Harding, E. K., Souza, I. A., Gandini, M. A., Gadotti, V. M., Ali, M. Y., Huang, S., Antunes, F. T. T., Trang, T., & Zamponi, G. W. (2023). Differential regulation of Ca v 3.2 and Ca v 2.2 calcium channels by CB 1 receptors and cannabidiol. British Journal of Pharmacology. https://doi.org/10.1111/bph.16035
Vancouver
Harding EK, Souza IA, Gandini MA, Gadotti VM, Ali MY, Huang S, et al. Differential regulation of Ca v 3.2 and Ca v 2.2 calcium channels by CB 1 receptors and cannabidiol. British Journal of Pharmacology. 2023. doi:10.1111/bph.16035
BibTeX
@article{Harding2023,
author = {Harding, Erika K and Souza, Ivana A and Gandini, Maria A and Gadotti, Vinícius M and Ali, Md Yousof and Huang, Sun and Antunes, Flavia T T and Trang, Tuan and Zamponi, Gerald W},
title = {Differential regulation of Ca v 3.2 and Ca v 2.2 calcium channels by CB 1 receptors and cannabidiol},
journal = {British Journal of Pharmacology},
year = {2023},
doi = {10.1111/bph.16035}
}
EUVIMED